Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Dementia in Parkinson's Disease.

Anderson KE.

Curr Treat Options Neurol. 2004 May;6(3):201-207.

PMID:
15043803
3.

"Brain-specific" nutrients: a memory cure?

McDaniel MA, Maier SF, Einstein GO.

Nutrition. 2003 Nov-Dec;19(11-12):957-75. Review.

PMID:
14624946
4.

Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R.

Clin Neuropharmacol. 2002 Nov-Dec;25(6):296-9.

PMID:
12469000
5.

Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).

Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU.

J Neurol. 2008 Feb;255(2):255-64. doi: 10.1007/s00415-008-0720-2.

PMID:
18204803
6.

Deep brain stimulation for the treatment of Parkinson's disease.

Volkmann J.

J Clin Neurophysiol. 2004 Jan-Feb;21(1):6-17. Review.

PMID:
15097290
7.

[Cognitive remediation and cognitive assistive technologies in schizophrenia].

Sablier J, Stip E, Franck N.

Encephale. 2009 Apr;35(2):160-7. doi: 10.1016/j.encep.2008.02.010. French.

PMID:
19393385
8.

Adherence to medication in patients with dementia: predictors and strategies for improvement.

Arlt S, Lindner R, Rösler A, von Renteln-Kruse W.

Drugs Aging. 2008;25(12):1033-47. doi: 10.2165/0002512-200825120-00005. Review.

PMID:
19021302
9.

Rivastigmine in Parkinson's disease dementia.

Chitnis S, Rao J.

Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):941-55. doi: 10.1517/17425250903105420. Review.

PMID:
19619073
11.

Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.

Dujardin K, Devos D, Duhem S, Destée A, Marié RM, Durif F, Lacomblez L, Touchon J, Pollak P, Péré JJ.

J Neurol. 2006 Sep;253(9):1154-9.

PMID:
16998649
12.

[Awareness of deficits and anosognosia in Alzheimer's disease].

Antoine C, Antoine P, Guermonprez P, Frigard B.

Encephale. 2004 Nov-Dec;30(6):570-7. Review. French.

PMID:
15738860
13.

Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Johannsen P.

CNS Drugs. 2004;18(12):757-68. Review.

PMID:
15377166
14.
15.

Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.

Wesnes K.

Drugs Today (Barc). 2007 Jun;43(6):349-59. Review.

PMID:
17612707
16.

Treatment of behavioural symptoms and dementia in Parkinson's disease.

Hanagasi HA, Emre M.

Fundam Clin Pharmacol. 2005 Apr;19(2):133-46. Review.

PMID:
15810893
17.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x.

PMID:
18503626
18.

Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?

Vale S.

Exp Biol Med (Maywood). 2008 Aug;233(8):941-51. doi: 10.3181/0707-MR-193. Review.

PMID:
18535172
19.

Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease.

York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, Jankovic J.

J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):789-95.

PMID:
17965146
20.

Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.

Goetz CG, Emre M, Dubois B.

Ann Neurol. 2008 Dec;64 Suppl 2:S81-92. doi: 10.1002/ana.21455.

PMID:
19127578
Items per page

Supplemental Content

Support Center